Chemomab Therapeutics announced that it has received a notification letter from the Listing Qualifications Department of the Nasdaq Stock Market, informing the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2).
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMMB:
- Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
- Chemomab’s CM-101 Shows Promise in PSC Trial
- Chemomab Therapeutics Announces $10 Million Private Placement
- Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis
- Chemomab: Publications ‘reinforce’ potential of I CCL24 antibody for PSC
